These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 14699986)

  • 1. Reducing major vascular events among VA primary care patients: an extraordinary opportunity.
    Hammermeister K; Gethoffer H
    Clin Cornerstone; 2003; Suppl 1():S2-10. PubMed ID: 14699986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.
    Geraci TS; Geraci SA
    J Cardiovasc Nurs; 2003; 18(5):389-95. PubMed ID: 14680343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study.
    Blacher J; Evans A; Arveiler D; Amouyel P; Ferrières J; Bingham A; Yarnell J; Haas B; Montaye M; Ruidavets JB; Ducimetière P;
    J Hypertens; 2004 Feb; 22(2):415-23. PubMed ID: 15076202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of coronary heart disease. Part I. Primary prevention.
    Liebson PR; Amsterdam EA
    Dis Mon; 1999 Dec; 45(12):497-571. PubMed ID: 10711300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of coronary heart disease: where do we go from here?
    Gotto AM
    Arch Intern Med; 2001 Apr; 161(7):922-4. PubMed ID: 11295953
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary heart disease in men.
    Cobble ME
    J Fam Pract; 2012 Jun; 61(6 Suppl):S29-33. PubMed ID: 22670244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
    J Hypertens; 1998 Feb; 16(2):127-37. PubMed ID: 9535138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Cholesterol Education Program: Adult Treatment Panel III--new recommendations for lifestyle and medical management of dyslipidemia.
    Berra K; Klieman L
    J Cardiovasc Nurs; 2003; 18(2):85-92. PubMed ID: 12680566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol.
    Green R; Kwok S; Durrington PN
    QJM; 2002 Dec; 95(12):821-6. PubMed ID: 12454325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and control of BP and lipids in patients with hypertension and additional risk factors.
    Welch V; Tang SS
    Am J Cardiovasc Drugs; 2007; 7(5):381-9. PubMed ID: 17953476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
    Ansell BJ; Watson KE; Fogelman AM
    JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
    Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New evidence in hypertension and hyperlipidaemia.
    Chapman N
    Heart; 2004 Jun; 90 Suppl 4(Suppl 4):iv14-7. PubMed ID: 15145906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study in primary care in patients without vascular disease comparing levels of coronary risk factors in those recommended for lipid-lowering drugs based on either absolute risk or absolute risk reduction.
    Ramachandran S; Croft P; Neary RH
    Prev Cardiol; 2003; 6(1):17-21. PubMed ID: 12624557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons.
    Rehring TF; Stolcpart RS; Hollis HW;
    J Vasc Surg; 2008 May; 47(5):1108-15. PubMed ID: 18372155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.